Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Molecular pathways: blockade of the PRLR signaling pathway as a novel antihormonal approach for the treatment of breast and prostate cancer.

Damiano JS, Wasserman E.

Clin Cancer Res. 2013 Apr 1;19(7):1644-50. doi: 10.1158/1078-0432.CCR-12-0138. Epub 2013 Mar 20. Review.

2.

Neutralization of prolactin receptor function by monoclonal antibody LFA102, a novel potential therapeutic for the treatment of breast cancer.

Damiano JS, Rendahl KG, Karim C, Embry MG, Ghoddusi M, Holash J, Fanidi A, Abrams TJ, Abraham JA.

Mol Cancer Ther. 2013 Mar;12(3):295-305. doi: 10.1158/1535-7163.MCT-12-0886. Epub 2012 Dec 27.

4.

CARD proteins as therapeutic targets in cancer.

Damiano JS, Reed JC.

Curr Drug Targets. 2004 May;5(4):367-74. Review.

PMID:
15134219
5.

Heterotypic interactions among NACHT domains: implications for regulation of innate immune responses.

Damiano JS, Oliveira V, Welsh K, Reed JC.

Biochem J. 2004 Jul 1;381(Pt 1):213-9.

6.

Integrins as novel drug targets for overcoming innate drug resistance.

Damiano JS.

Curr Cancer Drug Targets. 2002 Mar;2(1):37-43. Review.

PMID:
12188919
8.

CLAN, a novel human CED-4-like gene.

Damiano JS, Stehlik C, Pio F, Godzik A, Reed JC.

Genomics. 2001 Jul;75(1-3):77-83.

PMID:
11472070
9.

Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR).

Hazlehurst LA, Damiano JS, Buyuksal I, Pledger WJ, Dalton WS.

Oncogene. 2000 Sep 7;19(38):4319-27.

10.

Integrin-mediated drug resistance in multiple myeloma.

Damiano JS, Dalton WS.

Leuk Lymphoma. 2000 Jun;38(1-2):71-81. Review.

PMID:
10811449
11.

Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines.

Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS.

Blood. 1999 Mar 1;93(5):1658-67.

Supplemental Content

Loading ...
Support Center